Occasionally, during the process of thawing cryopreserved stem cells just prior to autologous reinfusion, we have observed the formation of fibrin clots inside plastic Cryocyte freezing containers (Baxter-Fenwal, Deerfield, IL, USA). These containers hold no more than 100 ml of stem cell product and are submerged in a 37°C water bath until complete thawing of the contents is visually observed before autologous reinfusion.
Bone marrow that has been collected into a bag of liquid culture media (Media 199, Gibco BRL Life Technologies, Grand Island, NY, USA) and heparin (for 1 liter volume, 200 ml of Media 199 and 10 000 IU of porcine heparin) was passed through a series of decreasing filter sizes (500 then 200 ) to remove bone spicules and fatty globules. A buffy coat in plasma was then prepared using a Haemonetics V-50 cell separator. An equal volume of 20% dimethyl sulfoxide (DMSO) in Media 199 was added to the buffy coat prior to cryopreservation. Peripheral blood stem cells collected by leukapheresis using acid citrate dextrose (ACD) as anticoagulant were concentrated by centrifugation at 700 g for 21 min at 22°C leaving an appropriate volume of plasma for resuspension. An equal volume of 20% DMSO in Media 199 and 20 IU heparin/50 ml was added to make a final stem cell preparation with 10% DMSO. The mononuclear cell concentration in the final processed bag of bone marrow or peripheral blood stem cells did not exceed 3 ϫ 10 8 /ml. The stem cell products were frozen using a controlledrate freezer programmed to cool down at Ϫ1°C/min to Ϫ12°C. Since latent heat of fusion is produced at the moment of phase change, a very rapid rate of freezing at Ϫ40°C in less than 1 min to Ϫ40°C was used at this time followed by a short warming period at ϩ20°C to Ϫ18°C. This was followed again by a controlled gradual temperature reduction of Ϫ°C/min down to Ϫ50°C, and Ϫ3°C/min down to Ϫ100°C. At this point stem cells were transferred and stored in the vapor phase of liquid nitrogen (Ϫ160°C) until the time of reinfusion.
Over a period of 40 months from January 1994 to April 1997, 169 autologous hematopoietic stem cell transplants were performed at the University of Oklahoma Health Sciences Center (OUHSC) for various indications. During this period, fibrin clot formation was observed in at least one of the Cryocyte bags of four patients (2.4%) during the thawing procedure. When this occurred, unclotted portions inside the Cryocyte bag were aspirated under sterile conditions and reinfused by intravenous push into a central venous catheter. Alternatively, when it was difficult to aspirate the liquid contents without contamination of clumped material, the whole contents were reinfused under gravity through a blood filter (80 ). No immediate untoward complications were observed during the infusion.
Panel A in Figure 1 shows an example of a thawed stem cell product with the fibrin clots appearing as 1-4 mm white chips dispersed uniformly in the container with a tendency to conglomerate. When examined histologically (panels B and C), precursor cells were observed to be sequestered in these clots in varying numbers. The exact amount of precursor cells lost was difficult to quantify and no attempt was made to determine the concentration or viability of mononuclear cells in the liquid portion of the bags after the clots had formed. Despite the formation of these clots and resultant reduction in total amount of precursor cells infused to recipients, the time to engraftment of either neutrophils or platelets was not significantly affected (see Table 1 ).
We are not certain what the mechanism of fibrin clot formation is in this setting. Cryopreserved stem cell products contain a significant proportion of monocyte or monocytoid cells (up to 50-60% in peripheral blood stem cell collections). Monocytes when activated have procoagulant activity by virtue of their secretion of tissue factor. 1, 2 Various stimuli known to stimulate monocyte procoagulant activity include lipopolysaccharide, 1 hypoxia, 3 and inflammatory cytokines like tumor necrosis factor. 4 In one study, frozen-thawed mononuclear cells fully retained their ability to produce tissue factor to the same extent as fresh cells but in contrast had a reduced fibrinolytic capacity. 5 It is conceivable that during the thawing procedure, rapid heat exchange or minor injury to a few mononuclear cells could have activated monocytes to secrete tissue factor and start the coagulation cascade with the diluted plasma present in the Cryocyte bags. There is no correlation of the monocyte count of the stem cell product with the probability of producing clots during the thawing procedure. The clot formation also did not occur in all of the thawed freezer bags of the same patient (2-4 per patient). Thus, the technique and conditions of thawing may sometimes create sufficient stimuli to cause procoagulant activity in the monocytes contained in the bags.
Since there has not been a significant impact on engraftment, no major changes have been made in processing of the stem cell product. However, the use of a plasma-free final suspension of stem cells for freezing may theoretically avoid or minimize the chances of fibrin clot formation during the thawing procedure. Count ϭ mononuclear cell count ϫ 10 8 /kg; N500 ϭ days to neutrophil count Ͼ500/l, P50K ϭ days to platelet count Ͼ50 000/l, BM ϭ bone marrow; M-PB ϭ mobilized peripheral blood; Bu ϭ busulfan; Cy ϭ cyclophosphamide; VP ϭ etoposide; TBI ϭ total body irradiation; Cb ϭ carboplatin. Numbers with brackets represent average number of days to engraftment corresponding to disease and source of stem cells for patients who did not have fibrin clot formation.
